Global Systemic Sclerosis Treatment Market to 2028 – by Drug Class, Disease Type, Route of Administration, Distribution Channel and Region –


DUBLIN–(BUSINESS WIRE)–The “Systemic Scleroderma Treatment Market Report, By Drug Class, By Disease Type, By Route Of Administration, By Distribution Channel, And By Region – Analysis of Size, Share, Outlook and opportunities, 2021-2028″ has been added to from offer.

Scleroderma is a chronic disease that usually affects the skin and connective tissue. Scleroderma is an autoimmune disease in which the body’s immune system produces extra collagen protein which deposits in the tissues and causes hardening of the skin. Collagen is a fibrous protein that is found in abundance in the body to provide strength and structure to the body.

The two main forms of scleroderma are localized and systemic. In localized scleroderma, only the skin is affected and no organs, while in systemic scleroderma the skin and underlying tissues are affected. Systemic sclerosis affects blood vessels and major organs in the body such as the heart, lungs, kidneys, gastrointestinal tract, and others. Systemic sclerosis can be classified into three main types, namely limited systemic sclerosis, diffuse systemic sclerosis, and scleroderma systemic sclerosis.

Limited scleroderma is one of the most common types of systemic sclerosis in which the curing effect of the disease is limited to the fingers and it is less likely to cause damage to internal organs. In diffuse systemic sclerosis, parts of the body such as the fingers, hands, arms, front of the trunk, legs, and face are affected. Diffuse systemic sclerosis also affects internal organs such as the heart and lungs. In systemic sclerosis sine scleroderma, no thickening of the skin is seen, but internal organs such as the heart, kidneys, and lungs can be severely damaged.

The growing prevalence of scleroderma, increasing research and development activities for the development of new therapies for the treatment of scleroderma, and the increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the main factors expected. to drive the growth of the global systemic sclerosis treatment market during the forecast period.

Main characteristics of the study:

  • This report provides an in-depth analysis of the global Systemic Sclerosis Treatment market and provides the market size (Million US$) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year.

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

  • This study also provides key insights into the market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.

  • It profiles leading players in the global Systemic Sclerosis Treatment market based on the following parameters: company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies and plans. future.

  • The information in this report would enable marketers and managing authorities of companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics.

  • The Global Systemic Sclerosis Treatment Market report is targeted at various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

  • Stakeholders would have an ease in making decisions through various strategic matrices used to analyze the global Systemic Sclerosis Treatment market

Detailed segmentation:

Global Systemic Sclerosis Treatment Market, By Drug Class:

  • Immunosuppressants

  • Calcium channel blockers

  • Proton pump inhibitors

  • Phosphodiesterase 5 inhibitors

  • Endothelin receptor antagonists

  • Prostacyclin analogues

  • Others (others include glucocorticoids, alkylating agents, and interleukin inhibitors)

Global systemic sclerosis treatment market, by disease type:

  • Limited systemic sclerosis

  • Diffuse systemic sclerosis

  • Systemic sclerosis Sinus sclerosis

Global systemic sclerosis treatment market, by route of administration:

Global Systemic Sclerosis Treatment Market, By Distribution Channel:

  • Hospital pharmacies

  • Retail pharmacies

  • Online pharmacies

Global Systemic Sclerosis Treatment Market, By Region:

  • North America

  • WE

  • Canada

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

  • Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Russia

  • The rest of Europe

  • Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea


  • Rest of Asia-Pacific

  • Middle East

  • GCC

  • Israel

  • Rest of the Middle East

  • Africa

  • South Africa

  • central Africa

  • North Africa

Company Profiles

  • Bristol-Myers Squibb Company

  • GlaxoSmithKline plc

  • Boehringer Ingelheim International GmbH

  • Corbus Pharmaceuticals

  • Actelion Pharmaceuticals Ltd.

  • Allergan

  • F. Hoffmann-La Roche Ltd.

  • biogenic

  • Novartis AG

  • Astra Zeneca

  • Celgene Corporation

  • Ono pharmaceutical co. ltd.

  • Teva Pharmaceutical Industries Ltd.

  • Aspen Holdings

  • Pfizer Inc.

  • Eli Lilly and company

  • Bayer AG

  • Amgen Inc.

  • Sanofi

  • Argentis Pharmaceuticals, LLC

For more information about this report visit


Comments are closed.